Terminated trials targeting Aβ hypothesis.
|Mechanism||RCT||End ||Enrollment||Duration||Main reasons |
|BACE1 inhibitor||Rosiglitazone||2009.2||693||24 weeks||Unimproved cognitive status|
|LY2886721||2013.8||128|| ||AE: 4 cases of liver damage in a phase 2 study in June 2013|
GSI/GSM||Semagacestat ||2011.5||164||>7 months||Unimproved cognitive status, but worsening functional ability; AE: skin cancers and infections|
|Avagacestat||2010.6||209||24 weeks||AE: gastrointestinal and dermatological abnormalities like diarrhea, nausea, vomiting, rash, and itching skin; nonmelanoma skin cancers; and worsened cognition|
|tarenflurbil ||2008.5||1684||18 months||Insufficient pharmacodynamics: poor capability to penetrate the BBB|
|Active immunology||AN1792||2003.9||375|| ||AE: 6 patients developed aseptic meningoencephalitis due cytotoxic T cell response in phase 2a trial|
|ACC-001||2014.2||126||24 months||Showed a serious side effect in phase 2 trial|
|Passive immunology||Bapineuzumab (AAB-001)||2012.6||1331||18 months||Showed no treatment effect on either cognitive or functional outcomes in two phase 3 trials|
|GSK3 inhibitor||Tideglusib (NP12)||2012.6||306||45 weeks||Missed its primary endpoint and some secondary endpoints|
|RCT: randomized controlled trial; AE: adverse event; BBB: blood brain barrier.|
Data sources: http://www.clinicaltrials.gov/; http://www.alzforum.org/.